Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

PURPOSE: We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a rare, aggressive, and highly lethal malignancy with poor patient outcomes and no systemic therapies with clinical benefit. M...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Subbiah, Vivek, Kreitman, Robert J., Wainberg, Zev A., Cho, Jae Yong, Schellens, Jan H.M., Soria, Jean Charles, Wen, Patrick Y., Zielinski, Christoph, Cabanillas, Maria E., Urbanowitz, Gladys, Mookerjee, Bijoyesh, Wang, Dazhe, Rangwala, Fatima, Keam, Bhumsuk
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
RAPID COMMUNICATION
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5791845/
https://ncbi.nlm.nih.gov/pubmed/29072975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.6785
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados